CellaVision AB (STO:CEVI) presented its Q1 2025 results on April 29, showcasing strong performance across all regions despite a challenging market environment. The company’s stock has responded ...
CellaVision AB reported a challenging first quarter of 2026, with significant revenue declines driven by inventory adjustments in the EMEA region. The company posted net sales of 166 million SEK, ...
Standardization and consistency for in-vitro diagnostics is of crucial importance, and the analysis and examination of blood samples is no exception. The Aerospray ® Hematology Pro Slide ...
HORIBA UK Ltd, Medical has introduced a new automated digital cell morphology solution in collaboration with CellaVision to help hematology laboratories simplify and expedite the performance of blood ...
CellaVision AB (STO:CEVI) reported its second-quarter 2025 results on July 18, showing organic growth of 7.6% despite facing significant currency headwinds. The company’s stock rose 1.44% to SEK 183.2 ...
HORIBA UK Ltd, Medical has introduced a new automated digital cell morphology solution in collaboration with CellaVision to help hematology laboratories simplify and expedite the performance of blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results